CardioLev Dynamics (HCS) 

 A system for prediction and prevention CHF (Congestive Heart Failure).

The company

CardioLev Dynamics (Heart Control System) was founded in 2008 by Dr. Levon Arakelyan, Dr. David Luria, Ran Amir and Leonid Khain. The   founders bring with them   many  years of experience within the fields of Mathematical Modeling, Physiology, software architecture and business development.

The product

The “HeartControl Analyzer” supported by a Dynamic Mathematical Model will collect in continuous mode information coming from implanted pacemaker's sensors. The Developed system will predict the heart failure dynamics, imitate the various scenarios of the condition correction, find the optimal solution and send the recommendations to the physician.

The need

The specific effects of heart failure on the body depend on whether it occurs on the left or right side. Over time, however, in either form of heart failure, the organs in the body do not receive enough oxygen and nutrients, and the body's wastes are removed slowly. Eventually, vital systems break down. The physicians treat patients with HF in accordance to the clinical manifestations: complaints and physical symptoms of the disease. Asymptomatic patients receive medical therapy intended to slow disease progression. However this "prophylactic» therapy usually has stable regime and does not taking into consideration dynamics of the disease before the manifest exacerbation.

Relative advantage

The advantages of our device are:

Predicting the HF dynamics before clinical symptoms of HF de-compensation became obvious;

Predicting the compensatory processes dynamics before achieving their negative influence;

Recommending the physician an optimal treatment for the prevention of HF decompensation and for minimization the negative consequences of the compensatory mechanisms at the early stage of the disease progression;

Finding and recommending the physician a personalized optimal solution for each patient according to peculiarities in functioning of patient heart, lung, vascular and metabolic systems.

IP-   patent application was submitted.